Clinical trial
A Study of AAV-hAADC-2 in Subjects With Parkinson's Disease
NCT00229736 · Genzyme, a Sanofi Company, Industry · Completed
Key facts
| NCT number | NCT00229736 |
|---|---|
| Title | A Study of AAV-hAADC-2 in Subjects With Parkinson's Disease |
| Official title | A Phase1 Open Label Safety Study of Intrastriatal Infusion of Adeno-Associated Virus Encoding Human Aromatic L-Amino Acid Decarboxylase (AAV-hAADC-2) in Subjects With Parkinson's Disease [AAV-hAADC-2-003] |
| Lead sponsor | Genzyme, a Sanofi Company, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Parkinson's Disease |
| Intervention type | Genetic |
| Interventions | AAV-hAADC-2 |
| Enrollment | 10 |
| Start date | Nov 1, 2004 |
| Primary completion | Mar 1, 2013 |
| Completion | Mar 1, 2013 |
| First posted | Sep 30, 2005 |
| Last update posted | Dec 4, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: